Maryland
How Enright v. Eli Lilly & Co. applies in Maryland: state-specific rules, key cases, and bar exam notes for Other.
Maryland recognizes the principles of liability for failure to warn and design defects as articulated in Enright v. Eli Lilly & Co. The Court emphasizes the importance of adequate warnings in pharmaceutical liability cases, aligning with the state's focus on consumer protection.
In Maryland, manufacturers have a duty to provide adequate warnings for their products, particularly regarding known risks, and can be held liable for injuries resulting from a failure to do so.
The court held that a manufacturer is liable for failure to warn if it can be shown that adequate warnings would have prevented the injury.
The court found that the adequacy of warnings is a question for the jury, especially when evidence suggests that the manufacturer had knowledge of risks.
The court ruled that a product must meet the safety expectations of consumers, with an emphasis on the need for strict product warnings.
Federal law, particularly through the Food, Drug, and Cosmetic Act, also requires adequate labeling and warnings but incorporates a more stringent preemption standard. In contrast, Maryland courts maintain that state tort claims can supplement federal requirements, thus allowing for broader consumer protection.
Understanding the standards of liability in pharmaceutical cases like Enright is critical for the Maryland bar exam, particularly among questions related to product liability and tort law.